Showing results (11-20 of 133) with videos related to
Sort By:
Pageof 14
Expert Review of Vaccines|December 3, 2015
Deciphering the human antigenomeAlessandro Sette, Theodore R Schenkelberg, Wayne C KoffAnnual Review of Medicine|January 31, 2002
Potential new therapies for the treatment of HIV-1 infectionJon H Condra, Michael D Miller, Daria J Hazuda, et al.Expert Review of Vaccines|April 25, 2017
A bioinformatics roadmap for the human vaccines projectRichard H Scheuermann, Robert S Sinkovits, Theodore Schenkelberg, et al.Expert Review of Vaccines|February 13, 2015
Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshopTheodore Schenkelberg, Marie-Paule Kieny, A E Bianco, et al.Vaccine|September 6, 2002
Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in miceXaioping Liang, Tong-Ming Fu, Hong Xie, et al.Nature Medicine|June 7, 2008
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humansDavid I Watkins, Dennis R Burton, Esper G Kallas, et al.Retrovirology|November 23, 2016
Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopesSupratik Das, Saikat Boliar, Nivedita Mitra, et al.Vaccine|March 20, 2016
Status of vaccine research and development of vaccines for HIV-1Jeffrey T Safrit, Patricia E Fast, Lisa Gieber, et al.Vaccine|August 27, 2013
Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countriesAllison Thompson, Alejandra Gurtman, Scott Patterson, et al.Revista Panamericana De Salud Publica = Pan American Journal of Public Health|August 14, 2013
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in MexicoMaricruz Gutiérrez Brito, Allison Thompson, Douglas Girgenti, et al.Pageof 14